WO2001072958A3 - Bladder cancer-specific peptides for diagnosis and therapy - Google Patents

Bladder cancer-specific peptides for diagnosis and therapy Download PDF

Info

Publication number
WO2001072958A3
WO2001072958A3 PCT/US2001/010116 US0110116W WO0172958A3 WO 2001072958 A3 WO2001072958 A3 WO 2001072958A3 US 0110116 W US0110116 W US 0110116W WO 0172958 A3 WO0172958 A3 WO 0172958A3
Authority
WO
WIPO (PCT)
Prior art keywords
diagnosis
therapy
bladder cancer
specific peptides
peptides
Prior art date
Application number
PCT/US2001/010116
Other languages
French (fr)
Other versions
WO2001072958A2 (en
Inventor
John V Frangioni
Lewis C Cantley
Michael A O'donnell
Original Assignee
Beth Israel Hospital
John V Frangioni
Lewis C Cantley
Donnell Michael A O
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital, John V Frangioni, Lewis C Cantley, Donnell Michael A O filed Critical Beth Israel Hospital
Priority to AU2001249608A priority Critical patent/AU2001249608A1/en
Publication of WO2001072958A2 publication Critical patent/WO2001072958A2/en
Publication of WO2001072958A3 publication Critical patent/WO2001072958A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to peptides which selectively bind to bladder tumor cells relative to normal (untransformed) bladder cells, e.g., also referred to herein as Bladder Tumor Cell-Specific (BTSC) peptides or BTCS binding sequence.
PCT/US2001/010116 2000-03-28 2001-03-28 Bladder cancer-specific peptides for diagnosis and therapy WO2001072958A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001249608A AU2001249608A1 (en) 2000-03-28 2001-03-28 Bladder cancer-specific peptides for diagnosis and therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19250500P 2000-03-28 2000-03-28
US60/192,505 2000-03-28

Publications (2)

Publication Number Publication Date
WO2001072958A2 WO2001072958A2 (en) 2001-10-04
WO2001072958A3 true WO2001072958A3 (en) 2002-03-21

Family

ID=22709946

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/010116 WO2001072958A2 (en) 2000-03-28 2001-03-28 Bladder cancer-specific peptides for diagnosis and therapy

Country Status (2)

Country Link
AU (1) AU2001249608A1 (en)
WO (1) WO2001072958A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1277728A1 (en) * 2001-07-18 2003-01-22 University of Lausanne Novel TTDA derivatives and their use as gadolinium chelators for MRI imaging
EP1472541B1 (en) 2002-01-10 2009-09-16 The Johns Hopkins University Imaging agents and methods of imaging naaladase of psma
CN101031319A (en) * 2003-12-11 2007-09-05 舍林股份公司 Radiosensitizer conjugate to improve the efficacy of radiolabeled drugs
CN101940553B (en) * 2009-07-10 2012-11-14 何彦津 Folic acid-vincristine targeted and slow-released nano-microspheres, prepared method and application thereof
WO2011038142A2 (en) * 2009-09-24 2011-03-31 The Regents Of The University Of California Bladder cancer specific ligand peptides

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999054460A2 (en) * 1998-04-21 1999-10-28 Metagen Gesellschaft Für Genomforschung Mbh Human nucleic acid sequences of normal bladder tissue
WO2000073348A2 (en) * 1999-06-02 2000-12-07 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
WO2000075327A1 (en) * 1999-06-02 2000-12-14 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
WO2001034796A1 (en) * 1999-11-10 2001-05-17 Compugen Ltd. Chordin-like homologs

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999054460A2 (en) * 1998-04-21 1999-10-28 Metagen Gesellschaft Für Genomforschung Mbh Human nucleic acid sequences of normal bladder tissue
WO2000073348A2 (en) * 1999-06-02 2000-12-07 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
WO2000075327A1 (en) * 1999-06-02 2000-12-14 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
WO2001034796A1 (en) * 1999-11-10 2001-05-17 Compugen Ltd. Chordin-like homologs

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] INTERNATIONAL, AMERICAN CHEMICAL SOCIETY, (COLUMBUS, OHIO, USA); ASHKENAZI ET AL.: "Methods and compositions for inhibiting neoplastic cell growth with utilization of chimeric polypeptides of PRO184 and PRO1186", XP002946443, accession no. STN Database accession no. 2000:881316 *
DATABASE CAPLUS [online] INTERNATIONAL, AMERICAN CHEMICAL SOCIETY, (COLUMBUS, OHIO, USA); BAKER ET AL.: "Human polypeptide and polynucleotide compositions for inhibiting neoplastic cell growth", XP002946442, accession no. STN Database accession no. 2000:861720 *
DATABASE CAPLUS [online] INTERNATIONAL, AMERICAN CHEMICAL SOCIETY, (COLUMBUS, OHIO, USA); SPECHT ET AL.: "Human bladder nucleic acid sequences and proteins and their use in drug screening and bladder tumor inhibition", XP002946441, accession no. STN Database accession no. 1999:691206 *
DATABASE CAPLUS [online] INTERNATIONAL, AMERICAN CHEMICAL SOCIETY, (COLUMBUS, OHIO, USA); TOPOROIK ET AL.: "Protein and cDNA sequences of human chordin-like homologs (CLH) and diagnostic and therapeutic uses thereof", XP002946444, accession no. STN Database accession no. 2001:360169 *

Also Published As

Publication number Publication date
AU2001249608A1 (en) 2001-10-08
WO2001072958A2 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
WO2006028429A3 (en) Peptides for targeting the prostate specific membrane antigen
WO2001092308A3 (en) Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
WO2002008285A3 (en) Il-17 molecules and uses thereof
WO2000005249A3 (en) Synthetic peptides and methods of use for autoimmune disease therapies
WO2001092581A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2002029086A3 (en) Nucleic acid sequences differentially expressed in cancer tissue
WO2002092818A8 (en) Streptococcus agalactiae genome sequence, use for developing vaccines, diagnostic tools, and for identifying therapeutic targets
WO2002074237A8 (en) Compositions and methods for the therapy and diagnosis of kidney cancer
WO2002020762A3 (en) Tnf receptor-like molecules and uses thereof
WO2000061622A3 (en) Genes associated with diseases of the kidney
WO2001072775A3 (en) Polynucleotides and polypeptides as well as methods for diagnosing and treating lung cancer
WO2001072822A3 (en) Genes involved in intestinal inflammatory diseases and use thereof
WO2001068705A3 (en) Il-17 receptor like molecules and uses thereof
WO2001049721A3 (en) Bacterial genes and proteins that are essential for cell viability and their uses
WO2000050607A3 (en) Goodpasture antigen binding protein
WO2001077168A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2001072958A3 (en) Bladder cancer-specific peptides for diagnosis and therapy
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
WO2002010388A3 (en) C3b/C4b COMPLEMENT RECEPTOR-LIKE MOLECULES AND USES THEREOF
AU6063900A (en) Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
WO2001066752A3 (en) Reproduction-specific genes
WO2001059120A3 (en) Il-17 like molecules and uses thereof
WO2002000174A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2001074903A3 (en) Cd20/ige-receptor like molecules and uses thereof
WO2000019210A3 (en) Determining the mechanism of beta-amyloid peptide generation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP